Skip to main content
. 2015 Jun 29;126(6):790–797. doi: 10.1182/blood-2015-03-633404

Table 3.

Factors associated with TTD

Characteristic Median TTD, weeks (range) HR 95% CI P value
Platelets
 ≥270 × 109/L 222 (194-250) Reference
 <270 × 109/L 103 (50-156) 1.80 1.11-2.92 .017
Peripheral blood blasts
 <1% 201 (164-238) Reference
 ≥1% 103 (26-181) 1.70 1.05-2.75 .030
Transfusion dependence 62 (14-110) 2.05 1.21-3.47 .008
Baseline spleen size (cm)* 0.99 0.95-1.04 .638
Diagnosis
 PPV-MF (N = 28) 240 (93-387) Reference
 PMF (N = 52) 119 (70-169) 1.48 1.06-2.17 .033
 PET-MF (N = 8) 211 (165-257) 1.00 0.587-1.70 .994
DIPSS
 Low/Int-1 (N = 39) 178 (116-240)
 Int-2/High (N = 49) 142 (47-237) 1.13 0.70-1.83 .618
 ASXL1+ (N = 19) 51 (42-60) 4.19 2.39-7.34 <.001
 EZH2+ (N = 7) 65 (29-101) 3.97 1.71-9.07 .002
 GATA2+ (N = 3) 60 (39-81) 2.88 0.8869.36 .127
 ≥1 mutation in ASXL1, EZH2, IDH1/2 (N = 26) 55 (43-67) 3.02 1.81-5.03 <.001
 ≥1 mutation in ASXL1, DNMT3A, or EZH2 (N = 22) 51 (41-61) 4.61 2.661-7.9 <.001
Number of mutations
 ≤1 (N = 48) 217 (165-269) Reference
 2 (N = 28) 142 (21-263) 1.71 1.00-2.90 .049
 ≥3 (N = 12) 55 (40-70) 5.74 2.74-12.1 <.001
Average dose intensity
 ≤10 mg BID (N = 20) 96 (37-155) Reference .365
 >10 to ≤20 mg BID (N = 39) 189 (161-217) 0.798 0.431-1.48
 >20 mg BID (N = 28) 119 (26-212) 1.18 0.627-2.32
Average dose intensity* 1.03 0.997-1.068 .071
G3/4 anemia/thrombocytopenia (N = 66) 166 (55-277) vs 154 (74-233) .454
 No G3/4 anemia OR thrombocytopenia (N = 21) 166 (55-277) Reference .396
 G3/4 anemia (N = 31) 188 (87-289) 0.942 0.505-1.76
 G3/4 thrombocytopenia (N = 18) 189 (158- 220) 0.713 0.333-1.53
 G3/4 anemia and thrombocytopenia (N = 18) 96 (11-181) 1.324 0.667-2.63
IWG spleen response (N = 57) 51 (31-71) Reference
217 (181-253) 0.281 0.164-0.481 <.001
*

Analyzed as a continuous variable by Cox regression.